看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
: b& i: S$ P* y4 ]. l! f
: `4 h) ?, O. V! s" u
. b2 l* t5 g! V# PCurrently available feasibility data for possible combination strategies.
7 Y3 J5 f1 C4 _- Z4 P2 h4 X————————————————————————————————, Q8 B7 `( i% Y+ s; E
Combination Feasibility according to preliminary data ' D2 ~" n8 ?4 a3 Q$ m. l; P, Z0 @
——————————————————————————————————
( G! k a. U6 _0 z2 gBevacizumab + sorafenib Yes, reduced dose
& V8 o9 B& D* x% l' LBevacizumab + sunitinib† No
+ z! Q/ c) h# [+ P1 p8 `" ABevacizumab + temsirolimus Yes
4 q2 j* D* B( N+ K3 T& J( \5 c) I/ IBevacizumab + everolimus Yes % V7 w) _* J4 ^# t
Sorafenib + sunitinib ?
( e. Z$ g- d+ [" P1 r1 JSorafenib + temsirolimus Yes, reduced dose
6 k( K( M+ u" VSorafenib + everolimus Yes, reduced dose % P- e' S/ ~+ B( o
Sunitinib + temsirolimus† No ; C- L8 Y0 C$ c
Sunitinib + everolimus ? 1 Y) e5 x% Q' k6 x. \8 i% D0 [
Temsirolimus + everolimus ?
) z ]$ ^+ w ~& O————————————————————4 Y5 ~; x8 i% [8 L; C# v* w
†Led to US FDA warning.
, J, i+ u- {! h' E \?: As yet unattempted combination.
' k: U, Y0 S& E |